Therapeutic Doses of Oral Methylphenidate Significantly Increase Extracellular Dopamine in the Human Brain

Methylphenidate (Ritalin) is the most commonly prescribed psychoactive drug in children for the treatment of attention deficit hyperactivity disorder (ADHD), yet the mechanisms responsible for its therapeutic effects are poorly understood. Whereas methylphenidate blocks the dopamine transporter (main mechanism for removal of extracellular dopamine), it is unclear whether at doses used therapeutically it significantly changes extracellular dopamine (DA) concentration. Here we used positron emission tomography and [(11)C]raclopride (D2 receptor radioligand that competes with endogenous DA for binding to the receptor) to evaluate whether oral methylphenidate changes extracellular DA in the human brain in 11 healthy controls. We showed that oral methylphenidate (average dose 0.8 +/- 0.11 mg/kg) significantly increased extracellular DA in brain, as evidenced by a significant reduction in B(max)/K(d) (measure of D2 receptor availability) in striatum (20 +/- 12%; p < 0.0005). These results provide direct evidence that oral methylphenidate at doses within the therapeutic range significantly increases extracellular DA in human brain. This result coupled with recent findings of increased dopamine transporters in ADHD patients (which is expected to result in reductions in extracellular DA) provides a mechanistic framework for the therapeutic efficacy of methylphenidate. The increase in DA caused by the blockade of dopamine transporters by methylphenidate predominantly reflects an amplification of spontaneously released DA, which in turn is responsive to environmental stimulation. Because DA decreases background firing rates and increases signal-to-noise in target neurons, we postulate that the amplification of weak DA signals in subjects with ADHD by methylphenidate would enhance task-specific signaling, improving attention and decreasing distractibility. Alternatively methylphenidate-induced increases in DA, a neurotransmitter involved with motivation and reward, could enhance the salience of the task facilitating the "interest that it elicits" and thus improving performance.

[1]  G. Rebec,et al.  Dopaminergic modulation of glutamate-induced excitations of neurons in the neostriatum and nucleus accumbens of awake, unrestrained rats. , 1996, Journal of neurophysiology.

[2]  J. Swanson,et al.  Medication treatment strategies in the MTA Study: relevance to clinicians and researchers. , 1996, Journal of the American Academy of Child and Adolescent Psychiatry.

[3]  K. Midha,et al.  Extensive and enantioselective presystemic metabolism of dl-threo-methylphenidate in humans , 1991, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[4]  I. Waldman,et al.  Association and linkage of the dopamine transporter gene and attention-deficit hyperactivity disorder in children: heterogeneity owing to diagnostic subtype and severity. , 1998, American journal of human genetics.

[5]  J. Perel,et al.  Metabolism and disposition of methylphenidate-14C: studies in man and animals. , 1974, The Journal of pharmacology and experimental therapeutics.

[6]  David J. Schlyer,et al.  Graphical Analysis of Reversible Radioligand Binding from Time—Activity Measurements Applied to [N-11C-Methyl]-(−)-Cocaine PET Studies in Human Subjects , 1990, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[7]  Darin D Dougherty,et al.  Dopamine transporter density in patients with attention deficit hyperactivity disorder , 1999, The Lancet.

[8]  N. Volkow,et al.  Reinforcing effects of psychostimulants in humans are associated with increases in brain dopamine and occupancy of D(2) receptors. , 1999, The Journal of pharmacology and experimental therapeutics.

[9]  N. Volkow,et al.  Comparison between intraperitoneal and oral methylphenidate administration: A microdialysis and locomotor activity study. , 2000, The Journal of pharmacology and experimental therapeutics.

[10]  A. Malhotra,et al.  Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[11]  D. Jasinski,et al.  Intravenous methylphenidate abuse. Prototype for prescription drug abuse. , 1991, Archives of internal medicine.

[12]  M. Solanto Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review and integration , 1998, Behavioural Brain Research.

[13]  N. Volkow,et al.  Blockade of striatal dopamine transporters by intravenous methylphenidate is not sufficient to induce self-reports of "high". , 1999, The Journal of pharmacology and experimental therapeutics.

[14]  N. Volkow,et al.  Effects of Blood Flow on [11C]Raclopride Binding in the Brain: Model Simulations and Kinetic Analysis of PET Data , 1994, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[15]  J S Fowler,et al.  Reproducibility of repeated measures of endogenous dopamine competition with [11C]raclopride in the human brain in response to methylphenidate. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[16]  D. Charney,et al.  Spect imaging of striatal dopamine release after amphetamine challenge in humans: Relationship between subjective effects and dopamine release , 1995, Schizophrenia Research.

[17]  N. Volkow,et al.  Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. , 1998, The American journal of psychiatry.

[18]  J. Swanson,et al.  More frequent diagnosis of attention deficit-hyperactivity disorder. , 1995, The New England journal of medicine.

[19]  M. Kuhar,et al.  Cocaine receptors on dopamine transporters are related to self-administration of cocaine. , 1987, Science.

[20]  P. Seeman,et al.  Anti-hyperactivity medication: methylphenidate and amphetamine , 1998, Molecular Psychiatry.

[21]  J S Fowler,et al.  Striatal binding of the PET ligand 11C‐raclopride is altered by drugs that modify synaptic dopamine levels , 1993, Synapse.

[22]  A. Grace,et al.  The tonic/phasic model of dopamine system regulation: its relevance for understanding how stimulant abuse can alter basal ganglia function. , 1995, Drug and alcohol dependence.

[23]  J. Biederman,et al.  Attention-deficit/hyperactivity disorder: a life-span perspective. , 1998, The Journal of clinical psychiatry.

[24]  P. Overton,et al.  Burst firing in midbrain dopaminergic neurons , 1997, Brain Research Reviews.

[25]  G. Koob Hedonic valence, dopamine and motivation. , 1996, Molecular psychiatry.

[26]  W. Oldendorf,et al.  Some relationships between addiction and drug delivery to the brain. , 1992, NIDA research monograph.

[27]  D. Segal,et al.  Effects of Methylphenidate on Extracellular Dopamine, Serotonin, and Norepinephrine: Comparison with Amphetamine , 1997, Journal of neurochemistry.

[28]  Jean Logan,et al.  Imaging endogenous dopamine competition with [11C]raclopride in the human brain , 1994, Synapse.

[29]  C. Schuster,et al.  Fixed-interval schedule of cocaine reinforcement: effect of dose and infusion duration. , 1973, Journal of the experimental analysis of behavior.

[30]  Klaus Tatsch,et al.  Increased striatal dopamine transporter in adult patients with attention deficit hyperactivity disorder: effects of methylphenidate as measured by single photon emission computed tomography , 2000, Neuroscience Letters.

[31]  M. Gold,et al.  From Coca Leaves to Crack: The Effects of Dose and Routes of Administration in Abuse Liability , 1988 .

[32]  J S Fowler,et al.  Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in the human brain. , 1995, Archives of general psychiatry.

[33]  R. Mark Wightman,et al.  Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter , 1996, Nature.

[34]  J. Lieberman,et al.  Behavioral and cardiovascular effects of intravenous methylphenidate in normal subjects and cocaine abusers , 1997 .

[35]  F Xavier Castellanos,et al.  Cerebrospinal Fluid Homovanillic Acid Predicts Behavioral Response to Stimulants in 45 Boys with Attention Deficit/Hyperactivity Disorder , 1996, Neuropsychopharmacology.

[36]  D. Parmelee,et al.  Population Pharmacokinetics of Methylphenidate in Children with Attention‐Deficit Hyperactivity Disorder , 1999, Journal of clinical pharmacology.